**Supplementary Material**

**Eligibility Criteria For Progestin Study, Lilongwe, Malawi**

Inclusion Criteria:

* Known HIV status, as documented by at least 2 concordant rapid tests (Determine and Uni-Gold, respectively). If the 2 rapid tests are discordant, then a confirmatory test will be done via Western blot.
* Female, pre-menopausal, age 18 to 45 years
* At least 2 regular, monthly cycles (~21-35 days) in the 3 months preceding study enrollment.
* If on hormonal or intrauterine contraception in the past, they must have been off for at least 6 months. If they were previously using DMPA, their last injection must have been ≥6 months ago.
* If recently pregnant, they must be at least 6 months postpartum
* Able and willing to provide informed consent
* Be otherwise a good candidate for study participation based on assessment by investigator or designee
	+ Interested in initiating a family planning method, specifically depot medroxyprogesterone acetate (DMPA) or the LNG implant (Jadelle)
	+ Willing to be randomized to receive either DMPA or LNG implant (Jadelle)
	+ Willing to wait 4-6 weeks after enrollment to receive this method and to use non-hormonal and non-intrauterine methods (such as abstinence or condoms) consistently during this period\*

\*Women will be counseled that if they enroll in this study, they will not receive their randomized contraceptive until they have had 2 menses after the enrollment date. During this time period, they cannot use any hormonal family planning methods (pills, injection, implant) or the intrauterine contraceptive device because use of such methods will alter the participant’s genital tract environment and secretions. Instead, they must use non-hormonal methods, such as abstinence, or condoms.

Exclusion Criteria

* Pregnancy (by clinical history or a positive urine pregnancy test at screening)
* Women currently using any hormonal contraceptive method
* Desire pregnancy within next 12 months
* Untreated visible genital ulcers or lesions on initial pelvic examination
* Known or suspected genital tract cancer (by clinical history or noted during initial pelvic examination).
* Contraindications to DMPA or LNG implant per the WHO medical eligibility criteria or judgment of clinician (contraindications include lactation within first 6 weeks postpartum, acute deep venous thrombosis or pulmonary embolism, lupus, migraine with aura, unexplained vaginal bleeding, current or history of breast cancer, severe cirrhosis, liver tumors, history of stroke, current or history of ischemic heart disease).
* Acute HIV infection (as documented by a known negative HIV test 6 months or less prior to screening).

Note: The initial pelvic exam will take place at Visit 1 after enrollment into the study. If untreated visible genital ulcers or lesions or suspected genital tract cancer are noted at this visit, the woman will be disenrolled and taken off study.